Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: The Southwest Oncology Group experience

Journal of Clinical Oncology

Volumn 4, Issue 3, 1986, Pages 295-305

  Dixon, D O ^a   Neilan, B ^a   Jones, S E ^a   Lipschitz, D A ^b   Miller, T P ^b   Grozea, P N ^b   Wilson, H E ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; LEVAMISOLE; PREDNISONE; VINCRISTINE;

ADVERSE DRUG REACTION; AGE; AGED; ALOPECIA; BACTERIAL INFECTION; BLOOD AND HEMOPOIETIC SYSTEM; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; CHILL; DIGESTIVE SYSTEM; DRUG THERAPY; FEVER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEART; HISTIOCYTIC LYMPHOMA; HUMAN; INTOXICATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHATIC SYSTEM; LYMPHOMA; MAJOR CLINICAL STUDY; NERVOUS SYSTEM; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PERIPHERAL VASCULAR SYSTEM; PHLEBITIS; PRIORITY JOURNAL; PROGNOSIS; SKIN TOXICITY; THERAPY;

EID: 0022602852     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1986.4.3.295     Document Type: Article

References (0)